Detalhe da pesquisa
1.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 387(4): 310-320, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830649
2.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646671
3.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Blood
; 135(10): 735-742, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945149
4.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
N Engl J Med
; 378(4): 331-344, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29224502
5.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Blood
; 134(15): 1238-1246, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331918
6.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770396
7.
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
Am J Hematol
; 96(10): 1211-1222, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251048
8.
Brentuximab Vedotin in Advanced Hodgkin's Lymphoma. Reply.
N Engl J Med
; 387(16): 1527-1528, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260801
9.
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Blood
; 132(10): 1013-1021, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30049811
10.
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Blood
; 131(16): 1805-1808, 2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386196
11.
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.
Am J Hematol
; 95(9): 1030-1037, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32419224
12.
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Haematologica
; 109(3): 982-987, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794803
13.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27458003
14.
Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma.
Haematologica
; 106(10): 2538, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882643
15.
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Br J Haematol
; 168(5): 663-70, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25316653
16.
Highlights in Hodgkin lymphoma from the 61st American Society of Hematology Annual Meeting: commentary.
Clin Adv Hematol Oncol
; 18 Suppl 6(2): 20-23, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33843910
17.
Initial Hodgkin treatment of the frail elderly.
Blood
; 130(26): 2813-2814, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29284610
18.
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.
Blood Adv
; 8(9): 2172-2181, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38271621
19.
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
Blood
; 117(20): 5314-20, 2011 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-21355087
20.
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
Cancers (Basel)
; 15(6)2023 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980646